News >

FDA Grants Olaparib Priority Review in BRCA+ Breast Cancer

Jason Harris
Published: Wednesday, Oct 18, 2017

The FDA has granted a priority review to a supplemental New Drug Application (sNDA) for olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings, according to AstraZeneca and Merck, the co-developers of the PARP inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication